Shuai Wang | Ischemic Stroke | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Mr. Shuai Wang | Ischemic Stroke | Best Researcher Award

Royal College of Surgeons | Ireland

Author Profile:

Scopus

Orcid

🎓 EARLY ACADEMIC PURSUITS

Shuai Wang began his academic journey in the field of pharmacy at Soochow University in Suzhou, Jiangsu Province. He earned his Bachelor of Pharmacy (2015–2019) and continued there for a Master’s degree in Pharmacy (2020–2023). His consistent academic excellence led him to pursue a PhD in Pharmacy at the Royal College of Surgeons in Ireland (2023–Present). His early dedication to the sciences laid the groundwork for a promising career in neuropharmacology.

🧪 PROFESSIONAL ENDEAVORS 

During his time at Soochow University, Shuai Wang was actively involved in numerous cutting-edge research projects under the guidance of Professor Hui-Ling Zhang. His work primarily focused on the molecular mechanisms underlying ischemic stroke and neuroinflammation, combining both in vivo and in vitro methodologies to produce meaningful scientific insights.

He contributed significantly to interdisciplinary research through collaborative pharmacodynamic studies, including:

  • DTIO’s role in promoting brain function recovery post-stroke (2021–2022)

  • VT101’s protective effects against myocardial ischemia/reperfusion injury (2020–2021)

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON ISCHEMIC STROKE

Wang’s research focus is neuropharmacology, with an emphasis on neuroinflammation, lipid metabolism, and cellular cross-talk following ischemic stroke. One of his landmark projects investigated the VEGFD/VEGFR3 pathway and its regulatory effect on IL-3/IL-3Rα interactions between astrocytes and microglia. His innovative approach used metabolic analysis and dual-model experimentation to explore cellular responses and pharmacological mechanisms.

📈 IMPACT AND INFLUENCE 

Shuai Wang has co-authored influential research papers in high-impact journals, including:

  • VEGFD/VEGFR3 mediates neuroinflammation and lipid metabolism reprogramming after ischemic stroke by regulating IL-3/IL-3Rα crosstalk between astrocytes and microglia.

  • The novel role and anti-inflammatory mechanisms of brain matrilin-3 in ischemic stroke, published in Cell Reports alongside distinguished co-authors.

These publications reflect his deep engagement with pressing medical challenges and his ability to contribute meaningfully to collaborative scientific inquiry.

🏅 ACADEMIC CITES AND RECOGNITIONS 

Wang's academic work has begun to garner citations and recognition within pharmacological and neuroscience communities. In recognition of his academic diligence and research output, he was awarded the Soochow University Master Scholarship consecutively in 2020, 2021, and 2022.

🚀 LEGACY AND FUTURE CONTRIBUTIONS 

Shuai Wang represents the next generation of innovative scientists in the field of neuropharmacology. With a strong academic foundation, extensive research training, and a visionary approach to disease mechanisms and treatment development, he is well-positioned to make future breakthroughs in stroke therapy and neurodegenerative disease research.

As he continues his doctoral research in Ireland, his future contributions are anticipated to shape both the theoretical landscape and clinical applications in neurology and pharmacotherapy.

📑 NOTABLE PUBLICATIONS

"VEGFD/VEGFR3 signaling contributes to the dysfunction of the astrocyte IL-3/microglia IL-3Rα cross-talk and drives neuroinflammation in mouse ischemic stroke"

Authors: Shuai Wang; Yi Guo; Rui-qi Cao; Yong-ming Zhu; Shi-gang Qiao; Hua-ping Du; Yuan Liu; Yuan Xu; Xian-yong Zhou; Lei Sun
Journal: Acta Pharmacologica Sinica
Year: 2025

 

Di-Hua Yu | Cardiopulmonary Resuscitation | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Mr. Di-Hua Yu | Cardiopulmonary Resuscitation | Best Researcher Award

Hubei Provincial Hospital of TCM | China

Author Profile:

Orcid

🎓 EARLY ACADEMIC PURSUITS

Di-Hua Yu laid a solid foundation for his medical and research career at the Hubei University of Chinese Medicine. He earned his Bachelor’s degree (2007–2012) with a stellar GPA of 3.9/4.0, receiving the prestigious First Prize Scholarship 🏅. He continued his academic excellence in his Master’s program (2012–2014), graduating with a GPA of 3.8/4.0 and being named an Outstanding Graduate 🌟. These early achievements highlighted his strong work ethic, deep curiosity, and aptitude for medical research.

💼 PROFESSIONAL ENDEAVORS

Since 2014, Yu has served as a Researcher in the Emergency Department at the Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 🇨🇳. His role places him at the heart of real-time emergency care, where he applies both traditional Chinese medical knowledge and modern evidence-based practices. His daily work bridges front-line clinical challenges and academic inquiry 📊🩺.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOPULMONARY RESUSCITATION

Yu’s research spans a multidisciplinary range of subjects that combine innovation with tradition:

  • 🏥 Emergency Medical Systems

  • ❤️ Cardiopulmonary Resuscitation

  • 💔 Cardiac Arrest

  • 📈 Statistical Analysis

  • 🤖 Artificial Intelligence in Medicine

His work reflects an evolving research focus that responds to modern healthcare challenges while respecting the insights of traditional Chinese medicine 🧪🌿.

🌐 IMPACT AND INFLUENCE

Di-Hua Yu has made meaningful scholarly contributions through publications such as:

  • “Factors Influencing Resuscitation Outcomes in Obese Out-of-Hospital Cardiac Arrest Patients” – Notfall + Rettungsmedizin 🚨

  • “Research Progress on the Toxicity of Tripterygium Wilfordii and Attenuated Synergistic Approaches” – YIXUE ZONGSHU

  • Multiple clinical studies on integrative therapies using Chinese herbal injections and formulations 🌱💉

These studies provide valuable insights into treatment effectiveness, especially in high-risk or emergency scenarios.

📚 ACADEMIC CITES

Yu’s ORCID profile (🔗 0000-0001-8628-4005) serves as his official research ID. While his presence on global platforms like Google Scholar and ResearchGate is still in development, the quality and diversity of his publications suggest growing academic recognition and future citation potential 📖✨.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Di-Hua Yu stands out as a forward-thinking medical researcher who blends traditional Eastern practices with modern Western methodologies. With rising global interest in AI-driven medical support systems 🤖 and personalized emergency care, Yu is well-positioned to contribute to:

  • 📡 Smarter Emergency Response Systems

  • 🔍 Data-Based Clinical Decision Tools

  • 🧬 Personalized Resuscitation Strategies

  • 🌏 Global Dialogues on Integrative Medicine

His legacy is expected to lie in fostering collaboration between ancient healing philosophies and next-generation technology 🛠️🌿.

📑NOTABLE PUBLICATIONS

"Factors influencing resuscitation outcomes in obese out-of-hospital cardiac arrest patients"

Authors: Wei-Qing Wang, Ying-Lin Wang, Zheng Zhu, Xiao-Xia Zeng, Gang Li, Di-Hua Yu
Journal: Notfall + Rettungsmedizin
Year: 2025

 

Hadi Emamat | Body Fat Distribution | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Hadi Emamat | Body Fat Distribution | Best Researcher Award

Bushehr University of Medical Sciences | Iran

Author Profile:

🎓 EARLY ACADEMIC PURSUITS

Dr. S.M. Hadi Emamat began his academic journey in the field of Nutrition Sciences at Shahid Beheshti University of Medical Sciences (SBMU), one of Iran's premier institutions. He completed his Bachelor's degree (2007–2011), followed by a Master's (2012–2015) and eventually earned his Ph.D. (2016–2020) in the same field. From the outset, Dr. Emamat demonstrated a strong commitment to exploring how diet influences health and disease, particularly focusing on metabolic and liver conditions.

👨‍🏫 PROFESSIONAL ENDEAVORS

Dr. Emamat currently serves as an Assistant Professor at the Department of Nutritional Sciences, School of Health and Nutrition, Bushehr University of Medical Sciences (BPUMS), Iran. His role encompasses both academic teaching and active research. He imparts knowledge through specialized courses, notably Medical Nutrition Therapy, aiming to train the next generation of nutrition professionals.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON BODY FAT DISTRIBUTION

Dr. Emamat's scientific research is primarily centered on the relationship between nutrition and chronic metabolic disorders. His scholarly work includes:

  • Investigating barberry's effect on cardiovascular risk factors in hypertensive patients for his Ph.D. thesis.

  • Studying the impact of onion consumption on features of nonalcoholic fatty liver disease (NAFLD) in animal models during his Master's research.

His broader research interests include:

  • Nutrition and Non-Alcoholic Fatty Liver Disease (NAFLD)

  • Nutrition and Cardiovascular Disease, particularly vascular function

  • Metabolic Syndrome

  • Nutrition and Gut Microbiota

These studies contribute to a growing body of evidence linking diet with systemic inflammation, blood pressure regulation, lipid profiles, and metabolic health.

🌍 IMPACT AND INFLUENCE

Dr. Emamat's work addresses global public health challenges, such as cardiovascular disease and NAFLD, which are on the rise due to poor dietary habits and sedentary lifestyles. His research provides valuable insights into how traditional foods and natural compounds can serve as functional interventions for chronic conditions. As an educator and investigator, he plays a pivotal role in shaping clinical nutrition strategies in Iran and beyond.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

With a solid foundation in clinical nutrition research and education, Dr. Emamat is well-positioned to make further advances in nutritional interventions for chronic diseases. His continued focus on evidence-based dietary solutions, integration of microbiome science, and public health applications will likely shape both policy and practice in the years ahead. His dedication signals a promising trajectory toward becoming a key figure in translational nutrition science.

📑 NOTABLE PUBLICATIONS

"The association between the visceral to subcutaneous abdominal fat ratio and the risk of cardiovascular diseases: a systematic review" 

Authors: Hadi Emamat, Ali Jamshidi, Akram Farhadi, Hamid Ghalandari, Mohadeseh Ghasemi, Hadith Tangestani
Journal: BMC public health
Year: 2024

"Association of serum 25-hydroxy vitamin D status with cardiometabolic risk factors and total and regional obesity in southern Iran: evidence from the PoCOsteo study" 

Authors: Alireza Nejabat, Hadi Emamat, Sima Afrashteh, Ali Jamshidi, Zahra Jamali, Akram Farhadi, Zahra Talkhabi, Iraj Nabipour, Bagher Larijani, Jörg Spitz
Journal: Scientific Reports
Year: 2024

Yuriy Borshchev | Ischemic-reperfusion injury | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Yuriy Borshchev | Ischemic-reperfusion injury | Best Researcher Award

Almazov National Medical Research Center | Russia

Author Profile:

Scopus

Orcid

🏅 BEST RESEARCHER PROFILE: DR. YURIY BORSHCHEV

👨‍🎓 EARLY ACADEMIC PURSUITS

Dr. Yuriy Borshchev was born on April 13, 1968, in Chisinau, Republic of Moldova. His academic journey began at Chisinau State University, where he pursued his studies from 1985 to 1992 in the Faculty of Biology and Soil Science, majoring in Biology with a specialization in Human and Animal Physiology. This foundational education laid the groundwork for his future contributions to physiological and biomedical research.

💼 PROFESSIONAL ENDEAVORS

Before fully immersing himself in academia, Dr. Borshchev gained extensive practical experience in various industries. Between 1992 and 2007, he worked in mechanical engineering and food processing enterprises in Moldova, advancing from logistics roles to leadership positions such as enterprise director. In 2007, he transitioned into scientific research, joining the Pavlov Institute of Animal Physiology as a laboratory assistant and later as a research associate.

By 2012, he earned his PhD (Candidate of Biological Sciences) with a dissertation focused on the effects of probiotic bacteria on intestinal enzymes in rats with dysbiosis. His career progressed as he became a senior researcher at the Institute of Experimental Medicine and, later, the Almazov National Medical Research Center, where he now serves as Head of the Physiological Microendoecology Department.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ISCHEMIC-REPERFUSION INJURY

Dr. Borshchev's work sits at the intersection of cardiology, gastroenterology, microbiology, and pathophysiology. His key contributions include:

  • Development of novel experimental biomedical models for studying inflammation and metabolic disorders.

  • Creation of a systemic inflammatory response model in rats, used to evaluate the therapeutic potential of probiotic bacteria.

  • Pioneering research into the influence of intestinal microbiota on myocardial resistance to ischemia-reperfusion injury.

  • Broad expertise in biochemical, histological, microbiological, and behavioral methodologies, as well as surgical experimentation on lab animals.

🌍 IMPACT AND INFLUENCE

Dr. Borshchev has significantly contributed to experimental medicine through:

  • Over 70 scientific publications, including 40 in SCI/SCIE journals and 18 indexed in Scopus/Web of Science/PubMed.

  • An H-index of 5, with a citation count of 22, reflecting ongoing recognition in specialized fields.

  • 8 completed research projects and 2 ongoing, amounting to over $800,000 USD in funding.

  • 5 industry-sponsored consultancy projects, demonstrating applied research impact.

  • Author and contributor to 8 books and proceedings with ISBNs.

  • One patent published, highlighting innovation in translational medical science.

📚 ACADEMIC CITES AND LEADERSHIP

In his academic and professional capacity, Dr. Borshchev:

  • Has served in editorial and reviewer roles for 2 journals/conferences.

  • Delivered 4 invited talks, attended 15 conferences, and visited 4 countries for international collaboration.

  • Supervised and graduated 2 research scholars, and is actively involved in collaborative scientific projects.

  • Maintains active profiles in global databases:

    • Scopus Author ID: 57206730176

    • Web of Science Researcher ID: IDE-1363-2014

    • elibrary.ru SPIN-code: 3454-4113

🧪 LEGACY AND FUTURE CONTRIBUTIONS

As a leading scientist at the Almazov National Medical Research Center, Dr. Borshchev continues to push the boundaries of experimental and translational medicine. His legacy is built on:

  • Bridging microbial ecology and systemic physiology.

  • Advancing knowledge in cardio-gastrointestinal interactions.

  • Training the next generation of scientists and building collaborative international partnerships.

Looking forward, Dr. Borshchev aims to expand his department's work into oncopharmacology and metabolic disease modeling, with the potential to influence both clinical therapies and preclinical standards.

🏆 AWARDS AND PROFESSIONAL AFFILIATIONS

Dr. Borshchev has been honored with 4 research awards, and holds 2 professional body memberships. He is committed to ethical research, demonstrated by his GLP-certified training in preclinical study protocols and laboratory animal handling.

🤝 COLLABORATIONS AND NETWORKING

  • 2 active MoUs with universities/industries.

  • 2 joint collaborative publications/projects.

  • Contributed to scientific communities across Russia, Europe, and other research-focused regions.

📌 CONCLUSION

Dr. Yuriy Borshchev exemplifies the qualities of a Best Researcher Award recipient: innovative, dedicated, and globally engaged. His work stands out for its relevance, depth, and potential to influence medical science well into the future.

📑 NOTABLE PUBLICATIONS

"Brain-Derived Neurotrophic Factor Cancels the Cardioprotective Effect of Interleukin-2 in a Model of Systemic Inflammatory Response in Rats"

Authors: I.Y., Burovenko, Inessa Yu , Y.Y., Borshchev, Yury Yu , S.M., Minasyan, Svetlana M. , ... O.V., Borshcheva, Olga V. , M.M., Galagudza, Mikhail M.
Journal: Bulletin of Experimental Biology and Medicine
Year: 2025

"Changes in the activity of amylase, alkaline phosphatase and lipase in placenta and umbilical cord blood in women in labor with gestational diabetes mellitus"

Authors: Elena V. Kolodkina; Sergey A. Lytaev; Michael M. Galagudza; Alexander B. Loginov; Tatyana M. Pervunina; Stanislav I. Sitkin; Yuri Yu. Borschchev; Olga V. Borschcheva
Journal: Medical academic journal
Year: 2025

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

Published on by Cardiology and Cardiovascular Medicine

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

The Affiliated Hospital of Southwest Medical University | China

Author Profile:

Scopus

👨‍⚕️ MR. FENGXU YU – PIONEER IN CARDIOVASCULAR INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Born in January 1976, Professor Fengxu Yu embarked on his medical journey with a strong academic foundation, earning his M.D. and later achieving qualifications as a doctoral supervisor. His passion for cardiovascular science led him to pursue postdoctoral training in France, equipping him with a global perspective and refined clinical research skills. This international exposure laid the groundwork for his future leadership in complex cardiovascular research and surgical practice.

💼 PROFESSIONAL ENDEAVORS

Currently serving as a Professor at The Affiliated Hospital of Southwest Medical University, Dr. Yu holds several distinguished roles:

  • Standing Committee Member, Cardiac Surgery Committee (CAMEA)

  • Committee Member, Heart Valve Committee (CRHA)

  • Vice Chair, Sichuan Thoracic & Cardiac Surgery Association

  • Academic Leader, recognized by the Sichuan Health Commission

  • Member, Asian Heart Valve Society, China Chapter

  • Recipient, Luzhou Top Talent Award

His consistent dedication has cemented his role as a leading figure in thoracic and cardiac surgery across China.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ATRIAL FIBRILLATION

Dr. Yu’s research endeavors focus on molecular and biomechanical mechanisms in cardiovascular disease, especially atrial fibrillation (AF), atherosclerosis, and aortic dissection. His current areas of exploration include:

  • Non-coding RNAs (e.g., circRNA/ceRNA networks) in AF pathogenesis

  • Application of induced pluripotent stem cells in modeling AF

  • Effects of shear stress on vascular endothelial health and its link to atherosclerosis

Through these efforts, Dr. Yu bridges basic science with clinical relevance, advancing the future of personalized medicine.

📊 IMPACT AND INFLUENCE

As a principal investigator, Dr. Yu has led nearly 20 major research projects funded by provincial and municipal institutions. He has also contributed to 30+ collaborative studies as a lead or co-investigator. His academic output includes over 50 peer-reviewed publications, with 12 articles indexed in SCI journals and 20+ papers in national core journals, showcasing his thought leadership in cardiovascular science.

📚 SELECTED RESEARCH PROJECTS

Some of Dr. Yu’s notable funded projects include:

  • Mechanism of Shear Stress-Downregulated Annexin A1 (2019)

  • circRNA-Regulated ceRNA Networks in AF (2025)

  • Personalized Warfarin Therapy Post-Valve Replacement (2022)

  • Hsa_circ_0025573—miR-133b—MMP9 in AF Pathogenesis (2022)

  • SRB1-Mediated Endothelial Injury in Atherosclerosis (2018)

These projects reflect a multidisciplinary approach to understanding and treating cardiovascular conditions.

🏅 ACADEMIC CITES AND MEMBERSHIPS

Professor Yu actively contributes to national and international academic bodies. His memberships include:

  • CAMEA – Cardiac Surgery Committee

  • CRHA – Heart Valve Committee

  • Sichuan Thoracic & Cardiac Surgery Association

  • Asian Heart Valve Society – China Chapter

These affiliations enhance his visibility in shaping future cardiac surgery standards and innovations.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Professor Fengxu Yu is a mentor, innovator, and academic leader. His mentorship of graduate students, collaboration with international institutions such as Heidelberg University, and continued work on translational research ensure a legacy of impactful science. As cardiovascular disease remains a global challenge, his pioneering work in non-coding RNA and biomechanical interactions is poised to redefine prevention and treatment strategies.

📑 NOTABLE PUBLICATIONS

"Myocardial infarction serum preconditioning bone marrow mesenchymal stem cell-derived exosomes enhance anti-fibrosis in rat myocardial infarction hearts" 

Authors: Y., Gan, Yang , C., Wang, Changyi , R., Liao, Ruili , ... H., Liu, Hui , Y., Fu, Yong
Journal: Molecular and Cellular Biochemistry.
Year: 2025

"Identification of the optimal reference genes for atrial fibrillation model established by iPSC-derived atrial myocytes" 

Authors: L., Li, Lei , Z., Zhao, Zijuan , Z., Liu, Zihao , ... Y., Nie, Yongmei , F., Yu, Fengxu
Journal: BMC Genomics
Year: 2024

"Postoperative delirium prediction after cardiac surgery using machine learning models" 

Authors: T., Yang, Tan , H., Yang, Hai , Y., Liu, Yan , ... Y., Zhang, Ying , F., Yu, Fengxu
Journal: Computers in Biology and Medicine
Year: 2024

Dongling Liu | TCM Pharmacology & Safety Research | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Dr. Dongling Liu | TCM Pharmacology & Safety Research | Best Researcher Award

Gansu University Of Chinese Medicine | China

Author Profile

Scopus

Google Scholar

🌟 PROF. DR. DONGLING LIU: A TRAILBLAZER IN CARDIOVASCULAR PHARMACOLOGY AND TCM INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Professor Dongling Liu began her academic journey with a Bachelor of Science in Pharmacy from Lanzhou University (2003–2007). Driven by a passion for pharmacological research, she pursued her Master’s and Ph.D. in Microbial Pharmacy at the same university, completing her doctorate in 2013. These formative years laid the foundation for her expertise in cardiovascular pharmacology and traditional Chinese medicine (TCM).

👩‍🏫 PROFESSIONAL ENDEAVORS

In September 2013, Professor Liu joined the School of Pharmacy at Gansu University of Chinese Medicine, progressing through roles from Lecturer to Professor. She is also the Vice President of the Longyao Industrial Innovation Research Institute since December 2023. Her global exposure includes research stints as a Visiting Scholar at UC San Diego and Training at Sydney Medical School, which have broadened her scientific perspective and collaborative network.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON TCM PHARMACOLOGY & SAFETY RESEARCH

With a specialization in cardiovascular pharmacology, Professor Liu has led four NSFC projects, primarily exploring molecular mechanisms behind doxorubicin-induced cardiotoxicity and the cardioprotective effects of TCM compounds. Her team’s discovery on kaempferol’s inhibition of mitochondrial ROS-dependent ferroptosis has opened new avenues in drug development, bridging traditional medicine with modern pharmacological science.

📚 IMPACT AND INFLUENCE

Professor Liu’s academic impact includes 40+ publications, 10+ in SCI-indexed journals, and 24 indexed in Scopus/Web of Science/PubMed. Her cumulative impact factor over the last 3 years is 29.1, with an H-index of 8 (Scopus ID: 57216257824). She has also secured 4 patents (8 pending) and published a reference book.

🏆 ACADEMIC CITES AND RECOGNITION

Her research contributions have earned prestigious awards including the First Prize of Gansu Provincial Science & Technology Progress Award, the Huangfu Mi TCM Science Award, and recognition such as the Gansu Outstanding Youth Fund, Feitian Youth Scholar, and Longyuan Talent Award. She serves as a peer reviewer for NSFC and is a member of multiple national academic committees.

🌍 COLLABORATIONS, PROJECTS & EXTENSION WORK

Professor Liu has completed 5 research projects, is actively engaged in 3 ongoing projects, and has collaborated on 20+ national and regional grants. She has led 2 consultancy/industry-sponsored projects worth $300,000 USD, and maintains functional MoUs with 2 institutions. As an extension leader, she directed policy reforms and standardization of Gansu's proprietary “Longyao” TCM materials, trained farmers, and established a health product demonstration base.

🎤 CONFERENCES, TALKS AND EDITORIAL ROLES

She has presented at 20 conferences, delivered 10 invited talks, and organized 20 workshops and conferences. She holds 3 editorial appointments, reflecting her expertise and reputation in pharmacological research.

🎓 RESEARCH SCHOLAR DEVELOPMENT

To date, Professor Liu has mentored 8 research scholars to graduation and currently supervises 5 ongoing doctoral candidates, contributing significantly to the cultivation of future pharmacology experts.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Professor Liu is not only a distinguished educator and researcher but also a visionary in innovative TCM-based pharmacotherapy. Her ongoing efforts aim to integrate traditional Chinese formulations with modern therapeutic standards, thereby contributing to global healthcare innovation. Her work ensures a lasting legacy in cardiovascular pharmacology, policy reform, and rural health development.

📑 NOTABLE PUBLICATIONS

"Exploring the efficacy and mechanism of Qingxuan decoction in treating opioid-induced constipation" 

Authors: Y., Zhang, Yarong , H., Cao, Haoshi , L., Su, Linling , ... D., Liu, Dongling , Y., Hai, Yang
Journal: Pharmacological Research - Modern Chinese Medicine
Year: 2025

"Effect of shenmai injection on anthracycline-induced cardiotoxicity: A systematic review and meta-analysis" 

Authors: Lili Yang, Xiaorui Liu,  Wen Yang,  Siqi Wang,  Zimu Li,  Yiming Lei,  Dongling Liu
Journal: Health Sciences
Year: 2024

Xu Zhichen | Esophageal Cancer | Best Research Article Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Xu Zhichen | Esophageal Cancer | Best Research Article Award

First Hospital of Quanzhou Affiliated to Fujian Medical University | China

Author Profile:

Scopus

👨‍⚕️ XU ZHICHEN: DEDICATED HEALER AND ESOPHAGEAL CANCER RESEARCHER

📚 EARLY ACADEMIC PURSUITS

Xu Zhichen was born in Putian, belonging to the Han ethnic group. His journey into the world of medicine began with a Bachelor's degree in Clinical Neurology from Luzhou Medical College (2005–2010). Demonstrating a strong passion for advancing cancer treatment, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013), focusing on Radiotherapy. His formal education laid a solid foundation for a career devoted to battling cancer, particularly esophageal cancer.

🏥 PROFESSIONAL ENDEAVORS

Following his master’s program, Xu Zhichen completed standardized clinical training at Quanzhou First Hospital (2013.9–2014.9). In September 2014, he officially joined the Radiotherapy Department at the same institution, where he continues to serve with distinction as an Associate Chief Physician. His dedication and skill have earned him certifications at every level of practice, including:

  • Practicing Physician Certificate (2016)

  • Official Appointment (2018)

  • Vice Senior Certification in Radiotherapy (2024)

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ESOPHAGEAL CANCER

Dr. Xu Zhichen is a recognized specialist in esophageal cancer, with his clinical and research efforts focusing on radiotherapy advancements. His notable academic contributions include:

  • Leading one provincial and one municipal research project.

  • Publishing 1 CSCD-indexed paper, 2 SCI-indexed papers, and multiple provincial-level papers.

These publications highlight his continuous effort to innovate and improve therapeutic strategies in radiation oncology.

🌐 IMPACT AND INFLUENCE

Dr. Xu’s influence extends beyond the clinic. He is a prominent figure in academic and professional circles:

  • Selected for the "Hundred Talent Program" at Quanzhou First Hospital – a mark of distinction for emerging medical leaders.

  • Serves as a Member of the Youth Committee of the Fujian Radiation Oncology Society, where he contributes to shaping policies and mentoring young oncologists.

📊 ACADEMIC CITES AND RECOGNITION

Though still in the early stages of senior-level research contribution, Dr. Xu’s SCI and CSCD publications have gained attention in the oncology community. His work is regularly cited in Chinese medical journals focused on radiotherapy protocols and esophageal cancer treatment methodologies, underlining his growing academic footprint.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

With a decade of focused clinical experience and increasing research output, Dr. Xu Zhichen is set to become a leading voice in radiation oncology in Fujian Province and beyond. His blend of practical excellence, academic commitment, and institutional leadership signals a promising trajectory. Future expectations include:

  • Expansion into multi-institutional clinical trials on esophageal cancer.

  • Publishing in high-impact international journals.

  • Training and mentoring the next generation of radiation oncologists.

📑 NOTABLE PUBLICATIONS

"A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma" 

Authors: Z., Xu, Zhichen , B., Su, Baoan , M., Lin, Mingqiang , Q., Xu, Qinghua , M., Qu, Mengke
Journal: Scientific Reports
Year: 2025

Heng Zhang | Cardiology | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Heng Zhang | Cardiology | Best Researcher Award

Fuwai Hospital, National Center for Cardiovascular Diseases | China

Author Profile

Scopus

Orcid ID

HENG ZHANG, M.D., PH.D. 🩺🫀

Dr. Heng Zhang is a distinguished medical professional specializing in cardiovascular surgery, with substantial contributions to the field of cardiovascular disease research, clinical practice, and health innovation. Holding a dual degree in medicine (M.D.) and a doctorate in philosophy (Ph.D.), Dr. Zhang’s academic and professional endeavors continue to shape the landscape of modern cardiovascular surgery, offering valuable insights into risk prediction, coronary revascularization, and the optimization of treatment strategies for cardiovascular diseases. His current role as an Associate Chief Physician at Fuwai Hospital, National Clinical Research Center of Cardiovascular Diseases, further cements his impact on the advancement of medical science.

EARLY ACADEMIC PURSUITS 🎓

Dr. Heng Zhang's academic journey began with an M.D. degree from Tianjin Medical University, where he graduated in 2010. During his studies, Dr. Zhang displayed a keen interest in cardiovascular health, which led him to pursue a Ph.D. in Cardiovascular Disease from Peking Union Medical College in 2015. Throughout his academic path, he also participated in key research exchanges, including a Visiting Scholar program in the USA at Duke Clinical Research Institute, further broadening his expertise in cardiovascular outcomes research and clinical performance measures.

PROFESSIONAL ENDEAVORS 👨‍⚕️🏥

Dr. Zhang’s clinical training began in 2009 with an internship at Nankai Hospital and continued through various stages of residency, including Peking Union Medical College Hospital and Fuwai Hospital. By 2015, he began specializing in cardiovascular surgery, eventually becoming an Attending Physician at Fuwai Hospital in 2019. His extensive clinical exposure includes pediatric and adult cardiac surgery, where he gained invaluable experience in treating complex heart conditions and improving patient outcomes through innovative surgical techniques.

CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOLOGY🔬💡

Dr. Zhang’s research has primarily focused on cardiovascular surgery registry, coronary revascularization risk prediction, and optimizing diagnostic and treatment strategies for cardiovascular conditions. He is deeply engaged in cardiovascular outcomes research, with particular attention to improving clinical performance measures and treatment protocols for heart diseases.

As the principal investigator and host of multiple high-impact research projects, Dr. Zhang has led groundbreaking studies such as evaluating the efficacy and safety of RN medications in preventing myocardial injury caused by ischemia-reperfusion and examining macrophage subtypes in coronary atherosclerosis. He has also significantly contributed to understanding valve replacement surgery and the long-term effects of heart valve interventions.

IMPACT AND INFLUENCE 🌍💪

Dr. Zhang's contributions to cardiovascular medicine have left a profound mark on clinical practice and research. Through his involvement in various research grants, including National Key Research and Development Plans of China and the Natural Science Foundation of China, Dr. Zhang has been pivotal in advancing both the theoretical and practical aspects of cardiovascular disease treatment and prevention. His work has also led to a shift in how cardiovascular surgeries are approached, particularly regarding patient-specific interventions in coronary artery malformation and atrial fibrillation.

His research projects have earned him several prestigious accolades, such as the Outstanding Reviewer for the Chinese Clinical Journal of Thoracic and Cardiovascular Surgery and the American Heart Association Travel Stipend Award. Dr. Zhang’s clinical and academic contributions are shaping future medical protocols, paving the way for a more personalized approach to heart disease treatment.

ACADEMIC CITES & HONORS 🏅📚

Dr. Zhang’s academic excellence is reflected not only in his research citations but also in the numerous honors and scholarships he has received. These include multiple first prizes for Young Investigator Awards, outstanding doctoral dissertations, and recognitions for clinical excellence. His impressive list of awards, including the Beijing Science and Technology Award (2016) and the Outstanding Doctoral Dissertation from Peking Union Medical College (2016), highlights his leadership and commitment to medical innovation.

LEGACY AND FUTURE CONTRIBUTIONS 🔮🏅

Dr. Zhang’s legacy lies in his consistent drive to innovate and advance cardiovascular surgery. His work with various research institutions and medical centers has laid a robust foundation for the continued improvement of heart disease diagnosis and treatment. As a principal investigator for several key projects and his role on editorial boards such as the Journal of American Heart Association, Dr. Zhang is poised to influence future cardiovascular research and practice for years to come.

Looking ahead, his research into heart valve replacement and atrial fibrillation is expected to lead to new clinical strategies that will enhance patient care globally. His future contributions are expected to redefine approaches to cardiovascular health, with an emphasis on personalized medicine and novel surgical techniques.

FINAL THOUGHTS 🧠💖

Dr. Heng Zhang is a leading figure in cardiovascular medicine, combining clinical expertise with cutting-edge research to make significant advancements in heart disease treatment. His future is one of continued excellence and innovation, as he works tirelessly to shape the future of cardiovascular care, improving the lives of patients worldwide.

NOTABLE PUBLICATIONS 📑

"Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study" 

  • Authors: Z., Li, Zhongchen , C., Yu, Chunyu , H., Zhang, Heng , Y., Zhao, Yan , Z., Zheng, Zhe
  • Journal: Cardiovascular Diabetology
  • Year: 2025

"Association of stress hyperglycemia ratio with short-term and long-term prognosis in patients undergoing coronary artery bypass grafting across different glucose metabolism states: a large-scale cohort study" 

  • Authors: Z., Li, Zhongchen , R., Chen, Runze , Z., Zeng, Zhiwei , H., Zhang, Heng , Z., Zheng, Zhe
  • Journal: Cardiovascular Diabetology
  • Year: 2025

"Clinical Outcomes of Surgical Revascularization Strategies Guided by Quantitative Flow Ratio in Primary Noncoronary Cardiac Surgery" 

  • Authors: L., Li, Linlin , H., Zhang, Heng , C., Rao, Chenfei , C., Liu, Chang , H., Fan, Hongguang
  • Journal: Journal of Thoracic Imaging
  • Year: 2024

"Association of carotid duplex ultrasonography screening with stroke and mortality among patients undergoing coronary artery bypass grafting" 

  • Authors: H., Zhang, Heng , D., Zhang, Danwei , J., Qu, Jianyu , X., Qian, Xiangyang , Z., Zheng, Zhe
  • Journal: Journal of Vascular Surgery
  • Year: 2024

"Impact of High Lipoprotein(a) on Long-Term Survival Following Coronary Artery Bypass Grafting" 

  • Authors: S., Yuan, Shuo , F., Li, Fangzhou , H., Zhang, Heng , Y., Zhao, Yan , Z., Zheng, Zhe
  • Journal: Journal of the American Heart Association
  • Year: 2024

Hideki Fujii | Cardiovascular Researches | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Hideki Fujii | Cardiovascular Researches | Best Researcher Award

Dr. Hideki Fujii, Osaka Metropolitan University, Japan

Dr. Hideki Fujii is a Lecturer at the Department of Hepatobiliary and Pancreatic Diseases, Osaka Metropolitan University Graduate School of Medicine, Japan. He earned his M.D. in 1998 and Ph.D. in Anatomy in 2004 from Osaka City University. With over two decades of clinical and academic experience, his expertise lies in liver cirrhosis therapeutics and gastrointestinal diseases. He has held several key roles at Osaka City University Hospital and affiliated institutions. Dr. Fujii is recognized for his research contributions, leadership in hepatobiliary medicine, and dedication to advancing treatment approaches for chronic liver and pancreatic disorders.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓 EARLY ACADEMIC PURSUITS:

Dr. Hideki Fujii began his academic journey at Osaka City University Medical School, where he earned his M.D. in 1998. His strong interest in anatomical sciences led him to pursue a Ph.D. in Anatomy, which he successfully completed in 2004 at the Department of Anatomy, Osaka City University Graduate School of Medicine. These formative years laid a solid foundation for his future specialization in hepatobiliary and pancreatic diseases.

💼 PROFESSIONAL ENDEAVORS:

Dr. Fujii’s clinical and academic career spans over two decades, demonstrating a continuous commitment to gastroenterology and hepatobiliary medicine:

  • 1998–2000: Began his residency at Osaka City University Hospital and Izumi City Hospital, gaining fundamental clinical experience.

  • 2004–2007: Served as a Junior Clinical Fellow at Osaka City University Hospital.

  • 2007–2009: Promoted to Senior Clinical Fellow in the same institution.

  • 2009–2014: Became a Lecturer in the Department of Hepatobiliary and Pancreatic Diseases at Osaka City University Hospital.

  • 2014–2016: Appointed Chief Physician in the Department of Gastroenterology at Osaka City Juso Hospital, reflecting his rising leadership in clinical practice.

  • 2016–2019: Served as a Specially Appointed Lecturer at the Endowed Chair for Liver Cirrhosis Therapeutics, Osaka City University.

  • 2019–2022: Promoted to Lecturer in both the Department and Endowed Chair at Osaka City University Graduate School of Medicine.

  • 2022–present: Currently holds the position of Lecturer in the Department of Hepatobiliary and Pancreatic Diseases at Osaka Metropolitan University Graduate School of Medicine.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Dr. Fujii’s core research revolves around hepatobiliary and pancreatic diseases, with a specialized emphasis on liver cirrhosis therapeutics. Through his association with the Endowed Chair for Liver Cirrhosis Therapeutics, he has played a significant role in the development and advancement of treatment protocols for chronic liver conditions.

His scientific contributions include:

  • Research on the pathophysiology of liver fibrosis and cirrhosis.

  • Clinical studies addressing novel therapeutics in gastroenterology.

  • Integration of anatomical research into clinical applications for liver and pancreatic disorders.

🌍 IMPACT AND INFLUENCE:

Dr. Fujii’s expertise has contributed to:

  • Enhanced clinical guidelines in hepatology and gastroenterology.

  • Training and mentoring of young physicians and fellows in the field of liver and pancreatic medicine.

  • Collaboration with national and international medical societies, influencing therapeutic standards in Japan and beyond.

📚 ACADEMIC CITES AND SCHOLARLY INFLUENCE:

Dr. Fujii’s academic work is:

  • Frequently cited in leading journals related to hepatology and gastroenterology.

  • Part of multicenter research studies, contributing valuable clinical data and interpretations.

  • Published in both Japanese and international peer-reviewed journals, solidifying his reputation in global medical research communities.

🌐LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Hideki Fujii is poised to leave a lasting legacy in the medical and academic community through:

  • Continued innovation in cirrhosis therapeutics.

  • Expanding research into pancreatic diseases and their systemic effects.

  • A commitment to teaching, mentoring, and collaborative research, ensuring the next generation of clinicians carry forward his mission of excellence in liver and pancreatic health.

🌟CONCLUSION:

Dr. Hideki Fujii is a highly respected expert in hepatobiliary and pancreatic medicine , with a career marked by dedication, innovation, and academic excellence. His extensive clinical experience and research in liver cirrhosis therapeutics have made significant contributions to improving patient care and advancing medical science. As a lecturer at Osaka Metropolitan University, he continues to inspire future medical professionals while pushing the boundaries of gastroenterology research. Dr. Fujii’s ongoing work promises to leave a lasting impact on both the academic and medical communities in Japan and beyond.

TOP NOTABLE PUBLICATIONS

Liver-derived Neuregulin1α stimulates compensatory pancreatic β cell hyperplasia in insulin resistance

Authors: T. Arai, E. Hayashi, S. Maeda, N. Kawada, N. Goda

Journal: Nature Communications

Year: 2025

Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review

Authors: Y. Kamada, Y. Sumida, H. Takahashi, E. Miyoshi, A. Nakajima

Is liver fibrosis more advanced in MetALD than in MASLD?

Authors: H. Fujii, Y. Kamada, A. Tokushige, T. Watanabe, N. Kawada

Year: 2024

Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis

Authors: T. Tsutsumi, T. Kawaguchi, H. Fujii, M.E. Rinella, Y. Sumida

Journal: Journal of Gastroenterology

Year: 2025

Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease

Authors: H. Ishiba, H. Fujii, Y. Kamada, T. Okanoue, A. Nakajima

Journal: Hepatology Communications

Year: 2024

Predictors of Immediate Deterioration of the Child-Pugh Classification From A to B After Transcatheter Arterial Chemo-Embolization for Treatment-Naive Hepatocellular Carcinoma

Authors: K. Asano, K. Kageyama, A. Yamamoto, N. Kawada, Y. Miki

Journal: Cancer Medicine

Year: 2024

Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease

Authors: K. Nouso, M. Kawanaka, H. Fujii, T. Kumada, T. Okanoue

Journal: Hepatology Research

Year: 2024

A case of secondary immune thrombocytopenia induced by atezolizumab plus bevacizumab therapy for hepatocellular carcinoma resulting in death from intracranial hemorrhage

Authors: K. Rinka, H. Fujii, A. Hagihara, M. Enomoto, N. Kawada

Journal: Nippon Shokakibyo Gakkai Zasshi

Year: 2024

Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy

Authors: R. Kozuka, M. Enomoto, Y. Yukawa-Muto, S. Uchida-Kobayashi, N. Kawada

Journal: Hepatology Research

Year: 2024

Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan

Authors: T. Tsutsumi, T. Kawaguchi, H. Fujii, A. Nakajima, T. Okanoue

Journal: Alimentary Pharmacology and Therapeutics

Year: 2024

Chunna Jin | Heart Failure | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Chunna Jin | Heart Failure | Best Researcher Award

Dr. Chunna Jin is the Associate Chief Physician at the Department of Cardiovascular Medicine, The Second Affiliated Hospital of Zhejiang University, China. She holds a Ph.D. in Cardiovascular Medicine from The Chinese University of Hong Kong and completed her postdoctoral fellowship at St. Francis Hospital, New York, USA. With a strong focus on ischemic heart disease, heart failure, and cardiovascular imaging, Dr. Jin combines advanced clinical expertise with cutting-edge research. She has published extensively in high-impact journals and is recognized for her international collaborations and contributions to innovative, patient-centered cardiovascular care.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Dr. Chunna Jin embarked on her academic journey with a profound interest in cardiovascular health. Her early dedication to medicine led her to pursue advanced studies in one of Asia’s top medical institutions. She earned her Ph.D. in Cardiovascular Medicine from the Faculty of Medicine, The Chinese University of Hong Kong (CUHK), where she laid the foundation for her clinical expertise and scientific research. This phase of her education not only enriched her clinical understanding but also honed her analytical skills, preparing her for a dynamic career in medicine.

🏥 PROFESSIONAL ENDEAVORS:

Currently, Dr. Jin serves as an Associate Chief Physician at the Department of Cardiovascular Medicine, The Second Affiliated Hospital of Zhejiang University (ZUCC) in China. In this pivotal role, she combines her clinical acumen with innovative medical practices to deliver high-quality cardiovascular care. Her career also includes international exposure as a Postdoctoral Research Fellow at St. Francis Hospital in New York, USA, a renowned center for cardiovascular treatment and research. This experience broadened her global perspective and deepened her understanding of diverse healthcare systems.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON HEART FAILURE:

Dr. Jin’s research is focused on cardiovascular diseases, with a particular interest in ischemic heart conditions, heart failure, and minimally invasive interventions. She has contributed extensively to studies involving cardiovascular pharmacotherapy, echocardiographic techniques, and electrophysiological diagnostics. Her interdisciplinary approach integrates clinical trials, translational medicine, and patient-centered innovations, contributing to a deeper understanding of heart health at both cellular and systemic levels.

🌍 IMPACT AND INFLUENCE:

Through her work, Dr. Jin has significantly influenced both clinical practice and academic research in cardiovascular medicine. Her international collaborations and her leadership at ZUCC have helped introduce cutting-edge diagnostic and therapeutic protocols into clinical settings. She is regarded as a mentor and guide by younger professionals in the field, and she has played a vital role in enhancing healthcare standards through training and development initiatives.

📚 ACADEMIC CITES AND PUBLICATIONS:

Dr. Jin has authored and co-authored numerous peer-reviewed journal articles, case reports, and conference papers, many of which are frequently cited in cardiovascular research. Her work appears in leading journals such as the European Heart Journal, Journal of the American College of Cardiology (JACC), and Circulation. These contributions have not only gained academic recognition but also have direct clinical applications that benefit patients worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Chunna Jin’s legacy is defined by her dedication to clinical excellence, innovative research, and global collaboration. Moving forward, she aims to pioneer personalized treatment models for cardiovascular patients, integrating genomic data and AI-driven diagnostics into mainstream medicine. Her vision includes fostering international research networks, enhancing telecardiology, and contributing to global health policy on cardiovascular disease prevention.

⭐CONCLUSION:

Dr. Chunna Jin is a trailblazing leader in cardiovascular medicine whose dedication to clinical excellence and research innovation continues to make a global impact. Her journey from prestigious academic institutions to influential hospital roles reflects her unwavering commitment to improving heart health. With a passion for mentoring, international collaboration, and advancing medical science, Dr. Jin stands as a role model for future healthcare professionals. Her ongoing efforts in precision medicine and digital healthcare promise a brighter, healthier future for cardiovascular patients worldwide. Dr. Jin’s legacy is one of compassion, expertise, and visionary progress.

TOP NOTABLE PUBLICATIONS

Association between Glycated Albumin and Adverse Outcomes in Patients with Heart Failure

  • Authors: Senmiao Chen, Guanzhong Chen, Yu Jin, Shiyu Zhu, Liangliang Jia, Chengchen Zhao, Chunna Jin, Meixiang Xiang

  • Journal: Journal of Diabetes Investigation

  • Year: 2024

First-Phase Ejection Fraction to Predict Adverse Outcomes in Patients with Heart Failure

  • Authors: Chunna Jin, Guanzhong Chen, Senmiao Chen, Hong Ma, Meixiang Xiang

  • Journal: International Journal of Cardiology

  • Year: 2024